DOCSLIB.ORG

Microsoft Outlook

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Microsoft Outlook Morris, Max From: Morris, Max Sent: Monday, March 22, 2021 11:38 PM To: Morris, Max Subject: 03/22/2021 Coronavirus Daily Recap This email is provided for informational, non-commercial purposes only. Use or reliance on the information contained in this email is at your sole risk. This email is not provided by or affiliated in any way with Ally Financial Inc. These updates are being shared to multiple organizations, individuals and lists who/which are bcc’d. Best effort we are sending Daily updates during the business week, typically in the evening, a Weekend Recap on Monday mornings, and any significant breaking news events provided anytime. Please note some numbers included in the Statistics and news stories come from various sources and so can vary as they are constantly changing and not reported at the same time. All communications are TLP GREEN and can be shared freely. Know someone who might want to be added to our Updates? Of course ask them first, and then have them send us an email to [email protected]. Live the message, share the message: Be safe – Stay home and limit travel as much as possible, self-quarantine if you or any members of your family are or may be sick, if you go out wear your mask – the right way, ensure safe social distancing, and practice good hygiene – wash your hands, avoid touching your face, and sanitize used items and surfaces. Need to find a vaccine? Here are a few good sites and resources we have come across that may help: CDC Vaccine Finder – https://vaccinefinder.org/ [Free government website where users can search for pharmacies and providers that offer vaccinations, currently limited number of states but expanding] Dr. B Standby list for COVID vaccines - https://hidrb.com/ [Sign-up website that connects eligible adults with leftover vaccines at risk of expiring] NBC News Plan Your Vaccine – https://www.nbcnews.com/specials/plan-your-vaccine/ [Website that walks you through eligibility, a timeline for when you can get vaccinated and where you can get a vaccine] Apple Maps App [Use the app to find vaccination location data from the US CDC's Vaccine Finder by searching or asking Siri, “Where can I get a Covid-19 vaccination?] Facebook Locator Tool [Access the social media’s Covid Information Center to see when and where to get vaccinated and get a link to make an appointment] Well hello there Everyone! A little later than usual but we weren’t going to forget ya. So, how was your Monday? We hope you had a great start to the first day of our new week. Yes, we already have one day in the books. Let’s keep that strong start going. Following are the major Headlines, the “Good Stuff”, US Snapshots, US Vaccinations, US Variant Cases, key Highlights, as well as key Statistics, Vaccine and Treatment information, US Restrictions and the Back to Normal Index related to the novel coronavirus pandemic. We’ve included a NEW couple of resources following to help with the new stimulus checks being sent out that we hope will help you figure out how much you may be getting and where the payment is. Tonight, we came across some inspiration from storyteller and author Brad Formsma, who offered us these words of wisdom to ponder: Whoever you are, no matter how much or how little you have to share, making the decision to give regularly to others - daily, weekly, or monthly - will enrich your life and change the lives of the people around you. Sharing. No matter what it is. No matter how small or insignificant it may seem. Just one act of kindness. It could be paying for someone’s coffee behind you in the drive-thru line. Saying thank you to a front-line worker at the grocery store. Letting someone know that you are thinking about them and just saying hi how are you. It doesn’t take much effort at all. And the reward you get back will be ten-fold. All you have to do is remember. So tomorrow find something to lift someone’s day. And tell me if it doesn’t bring a warm fuzzy to your heart and soul . Want to get information on the latest stimulus checks? Here are two sites that can help: 1 NEW Want to check on the status of your stimulus payment? Use the Get My Payment tool at https://www.irs.gov/coronavirus/get-my-payment to check if it has been scheduled. NEW Want to find out how much your stimulus check will be? Use the CNN calculator at https://www.cnn.com/2021/03/09/politics/third-stimulus-check-calculator/index.html. CVOB Website individual US State, US County, Global Trending Charts and Data as well as US Vaccinations, US Restrictions and our Communications Archive can be found at https://www.sunknighty.net/. Headlines New cases of Covid-19 are once again on the rise across more than half of the US and the recent drop in hospitalizations is slowing, Centers for Disease Control and Prevention Director Dr. Rochelle Walensky warned Monday, adding that she's worried the country could see "another avoidable surge" of Covid-19 sparked by variants if mitigation measures – such as mask-wearing, physical distancing and avoiding crowds or travel – are not followed. The White House is encouraging governors, as well as the private sector, to maintain or reimpose coronavirus restrictions as new case rates remain high and some states are lifting guidelines, with US Centers for Disease Control and Prevention director Dr. Rochelle Walensky saying Monday the administration is working to “slow down the relaxation” but some states have lifted restrictions on restaurant capacity and other retail businesses in recent weeks, with some states relaxing mask mandates. About 1 in 4 people in the US - nearly 83 million people - have received at least one dose of vaccine, and more than 1 in 8 - about 45 million people - have been fully vaccinated, Centers for Disease Control and Prevention data released Monday shows. More than two-dozen travel-industry groups are urging the Biden administration to lift international travel restrictions for vaccinated individuals and other measures to revive demand for trips, and Airlines for America - which represents most large U.S. carriers, as well as the largest flight attendant union, hotel and airport associations and the US Chamber of Commerce - called on the White House to come up with a “roadmap” by May 1 toward rescinding travel bans that have devastated international air travel with Europe. DoorDash announced Monday it will begin same-day deliveries of US Food and Drug Administration authorized Covid-19 PCR tests across the US, and in a new release the online food and product delivery platform says it teamed up with digital health companies Vault Health and Everlywell, giving consumers access to “two COVID-19 home collection kits that received FDA Emergency Use Authorization.” Maria van Kerkhove, the World Health Organization’s technical lead for coronavirus response, said Monday that global cases of Covid-19 have risen for the fifth consecutive week, and that the agency is seeing worrying trends in Europe, as well as number of areas, with four of the five regions reporting an increase in transmission. Germany is extending its lockdown until April 18 and calling on citizens to stay at home for five days over the Easter holidays to try to break a third wave of the COVID-19 pandemic, German Chancellor Angela Merkel said early on Tuesday. Ontario, Canada’s largest province, declared it was at the beginning of a third wave of the pandemic Monday, pointing to increasing case counts, hospitalizations and variants of concern, sobering news for the majority of residents who have been in some state of lockdown since late last year. The second batch of Covid-19 stimulus checks will be issued this week, the Biden administration announced Monday, with many of the payments expected to come via paper check or prepaid debit card and additional batches will be made weekly going forward, according to a statement from the US Department of the Treasury, the Internal Revenue Service and the Bureau of the Fiscal Service. Microsoft said that starting March 29 more employees can return to its Washington headquarters, with the company allowing employees who work at its Redmond sites and nearby campuses to choose between returning to work full-time, continuing to work remotely or implementing a hybrid model. Dealing with stress during the pandemic has caused physical changes for many Americans - some have gained undesired weight, and others have unintentionally lost weight, with a American Psychological Association's Stress in America pandemic survey that polled 3,013 adults in the US finding that the majority, 61%, experienced undesired weight changes, with forty-two percent of adults gaining more weight than they intended, of those, the amount they reported gaining averaged 29 pounds, and ten percent said they gained more than 50 pounds. 2 Krispy Kreme launched a new program Monday to give a free doughnut to customers who present their coronavirus vaccine cards, a deal that started today and lasts through the rest of 2021, the North Carolina-based company announced in a release, with customers able to bring their valid coronavirus vaccination cards to any shop in the US every day for the rest of the year to get a free Original Glazed doughnut — one per day. The Good Stuff: A Virginia resident has become a popular person in her neighborhood and across the region for her ability to get COVID-19 vaccination appointments on websites that other people find excruciatingly difficult to navigate.
Load more

Recommended publications
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • National Emergency Management Organisation (Nemo) Ministry of National Security St
    NATIONAL EMERGENCY MANAGEMENT ORGANISATION (NEMO) MINISTRY OF NATIONAL SECURITY ST. VINCENT AND THE GRENADINES WEST INDIES Tel: 784-456-2975, Fax: 784-457-1691, Email: [email protected] or [email protected] ______________________________________________________________________________ ___________________________________________________________________________________________________________________ HEALTH SERVICES SUBCOMMITTEE PROTOCOL FOR THE ENTRY OF FULLY VACCINATED TRAVELLERS TO ST. VINCENT AND THE GRENADINES – revised 10/08/2021 AIM: The safe entry of travellers to St. Vincent and the Grenadines in a manner that reduces the risk of the importation and subsequent transmission of COVID-19 in St. Vincent and the Grenadines. OBJECTIVES: 1. To establish the risk of the arriving traveller introducing new COVID-19 cases to SVG; 2. To minimize exposure of residents of SVG to new COVID-19 cases; 3. Early identification of potential exposure to COVID-19 and 4. Early containment of new COVID-19 cases. ESTABLISH RISK OF ARRIVING TRAVELLER: The arriving traveller will: 1. Complete the Pre-Arrival Form available at health.gov.vc And the Port Health Officer will: 1. Review Port Health form for each arriving passenger. 1 PHASED PROCESS OF ENTRY OF FULLY VACCINATED TRAVELERS TO ST. VINCENT AND THE GRENADINES: TESTING & QUARANTINE: PHASE #16 - Commencing Wednesday, August 11, 2021: 1. Where ‘Fully Vaccinated Travelers’ are those persons who: a. Have completed a vaccination regimen with one of the following COVID-19 vaccines recognized by the Ministry of Health, Wellness and the Environment of St Vincent and the Grenadines: i. AstraZeneca – Oxford AstraZeneca (Vaxzevria), COVISHIELD, AstraZeneca COVID-19 vaccine by SK Bioscience; ii. Pfizer-BioNTech COVID-19 vaccine; iii. Moderna COVID-19 vaccine; iv.
    [Show full text]
  • COVID Vaccine Quick Reference Chart for Timeline
    Pfizer-BioNTech Moderna Johnson & Johnson Novavax Oxford-AstraZeneca Sputnik V CureVac Sinopharm's BBIBP-CorV MOA mRNA vaccine mRNA vaccine Adenovirus vector vaccine Protein-based vaccine Adenovirus vector vaccine Adenovirus vector vaccine mRNA vaccine Inactivated virus Dosing 2 doses, 21 days apart 2 doses, 28 days apart 1 dose 2 doses, one month apart 2 doses, three months apart Sputnik Light requires one dose. 2 doses, four weeks apart 2 doses, three weeks apart Schedule The vaccine has been In a press release, the Gamaleya National D shown to be 89.3% effective Center of Epidemiology and Microbiology in in large-scale UK trials. Moscow claimed a large-scale Russian e 72% in the U.S. and 66% globally 76% in a U.S. study against Significantly, it is the first study saw 92% efficacy for its vaccine. t against moderate-to-severe symptomatic COVID-19; 100% 95% at least 7 days after 94.1% at least 14 days jab shown to be effective However, other scientists have voiced Efficacy results are presumed to 78% according to the World Health Efficacy disease; 85% effective against effective severe disease; 85% a dose 2 after dose 2 against the new UK variant concerns this claim is based on too few be released in May 2021. Organization severe disease, 28 days after a efficacy against symptomatic of COVID-19 in such a trial. cases. Although the vaccine was trialled on i single dose. COVID-19 in those 65+ 96% against original 18,000 people, the efficacy claim has been l coronavirus, 86% against B.
    [Show full text]
  • Comparative Characteristics of the Main Coronavirus Vaccines
    Acta Scientific MICROBIOLOGY (ISSN: 2581-3226) Volume 4 Issue 9 September 2021 Editorial Comparative Characteristics of the Main Coronavirus Vaccines Pavel F Zabrodskii* Received: June 23, 2021 Saratov Medical University "REAVIZ", Saratov, Russian Federation Published: August 01, 2021 *Corresponding Author: Pavel F Zabrodskii, Saratov Medical University "REAVIZ", © All rights are reserved by Pavel F Saratov, Russian Federation. Zabrodskii. Since the beginning of the epidemic, vaccine development has been a priority for all developed countries. According to WHO (26 adenovirus rather than human adenovirus should reduce the risk virus. The fact that the vaccine was developed using chimpanzee January 2021), more than 60 vaccines worldwide are already in of allergic reactions and severe side-effects. However, the disadvan- clinical trials. More than 170 are being tested on animals. There tage of this product, as with all vector vaccines, is that the technol- ogy itself is new and has not previously been used in health care. One of the pluses for vector drug manufacturers is their speed of are 22 vaccines that have made it through the final phase of testing. creation. The vaccine is registered for use in the European Union. It The vaccine, developed by US company “Pfizer” and its German is licensed for emergency use in another 20 countries. clinical trials ended on 9 November 2020. In addition to EU coun- partner “BioNTech”, has been registered first in the EU. Phase III - ceutical company Sinovac Biotech, which has shown controversial tries, the vaccine is used in Australia, Saudi Arabia, Switzerland, “CoronaVac” is an inactivated vaccine from Chinese biopharma - Norway, Iceland, Serbia and some other countries.
    [Show full text]
  • The Fast Approval and Slow Rollout of Sputnik V: Why Is Russia's Vaccine
    Article The Fast Approval and Slow Rollout of Sputnik V: Why Is Russia’s Vaccine Rollout Slower than That of Other Nations? Elza Mikule 1,*,† , Tuuli Reissaar 1,† , Jennifer Villers 1,† , Alain Simplice Takoupo Penka 1,† , Alexander Temerev 2 and Liudmila Rozanova 2 1 Global Studies Institute, University of Geneva, 1205 Geneva, Switzerland; [email protected] (T.R.); [email protected] (J.V.); [email protected] (A.S.T.P.) 2 Institute of Global Health, University of Geneva, 1202 Geneva, Switzerland; [email protected] (A.T.); [email protected] (L.R.) * Correspondence: [email protected] † These authors contributed equally. Abstract: The emergence of the SARS-CoV-2 pandemic in the beginning of 2020 led to the deployment of enormous amounts of resources by different countries for vaccine development, and the Russian Federation was the first country in the world to approve a COVID-19 vaccine on 11 August 2020. In our research we sought to crystallize why the rollout of Sputnik V has been relatively slow considering that it was the first COVID-19 vaccine approved in the world. We looked at production capacity, at the number of vaccine doses domestically administered and internationally exported, and at vaccine hesitancy levels. By 6 May 2021, more first doses of Sputnik V had been administered Citation: Mikule, E.; Reissaar, T.; abroad than domestically, suggesting that limited production capacity was unlikely to be the main Villers, J.; Takoupo Penka, A.S.; reason behind the slow rollout. What remains unclear, however, is why Russia prioritized vaccine Temerev, A.; Rozanova, L.
    [Show full text]
  • Building Visualizations to Uncover Insights in Clinical Trial and Pipeline Data
    Building visualizations to uncover insights in clinical trial and pipeline data: a COVID-19 vaccine case study Matt Eberle, Lead Developer, Analytics and Custom Solutions, BizInt Solutions, Inc. Diane Webb, President and Co-Founder, BizInt Solutions, Inc. Wednesday, March 24, 2021, 2:00 pm ET This session will start momentarily…. Webinar Host Susie Corbett PHT Chair Pharmaceutical & Health Technology Community https://connect.sla.org/pht/home Matt Eberle Lead Developer, Analytics and Custom Solutions, BizInt Solutions, Inc. [email protected] Following over ten years of experience at Wyeth, Pfizer and Sunovion as a Senior Information Scientist and Pharmaceutical Information Analyst, since 2013 Matt has helped BizInt customers use the BizInt Smart Charts and VantagePoint tools to create new solutions to address their challenges and problems. Matt lives outside Boston, MA. Diane Webb President and Co-Founder, BizInt Solutions, Inc. [email protected] Diane has over 30 years of experience managing the development of software tools to analyze and present competitive intelligence information, with a focus on drug pipeline, clinical trial and patent data. In 1996 Diane and John Willmore started BizInt Solutions to develop and market the BizInt Smart Charts product family. Diane & John live near Seattle, WA, with their current pack of four longhaired dachshunds. Building visualizations to uncover insights in clinical trial and pipeline data: a COVID-19 vaccine case study Part I: Dashboard visualizations and initial challenges PHT Pharma
    [Show full text]
  • COVID-19 Situation Report 474
    For citation: Centre for Infectious Disease Epidemiology and Research-NUS. COVID-19 Situation Report 474. 30 July 2021 July 30 COVID-19 Situation Report 474 Centre for Infectious Disease Epidemiology and Research (CIDER) For citation: Centre for Infectious Disease Epidemiology and Research-NUS. COVID-19 Situation Report 474. 30 July 2021 s i. Background In December, China notified the World Health Organization (WHO) of several cases of human respiratory illness, which appeared to be linked to an open seafood and livestock market in the city of Wuhan. The infecting agent has since been identified as a novel coronavirus, previously known as 2019-nCoV and now called SAR-CoV-2; The new name of the disease has also been termed COVID-19, as of 11th February 2020. Although the virus is presumed zoonotic in origin, person-to-person spread is evident. Screening of travellers, travel bans and quarantine measures are being implemented in many countries. Despite these precautions, it is anticipated that more cases will be seen both inside China and internationally. The WHO declared the outbreak of COVID-19 constitutes a Public Health Emergency of International Concern on 30 January. On 11 March, 2020, WHO declared the coronavirus outbreak a pandemic as the global death toll rose above 4,600 and the number of confirmed cases topped 125,000. This report aims to update Global Risk Assessment, Global Epidemiology, Quarantine Orders, Travel Ban/Advisory by countries, WHO’s and CDC’s Guidance and Protocols and Scientific publication on a daily basis. New updates in the tables are bolded. 1 | P a g e Centre for infectious di sease epidemiology and research For citation: Centre for Infectious Disease Epidemiology and Research-NUS.
    [Show full text]
  • STI Policies in Russia Amid COVID-19 3
    ___________________________________________________________________________ 2021/SOM3/PPSTI/007 Agenda Item: 10d Science, Technology and Innovation Cooperation for the Sustainable and Resilient System After COVID-19 from the Russian Perspective Purpose: Information Submitted by: Russia 18th Policy Partnership on Science, Technology and Innovation Meeting 25-26 August 2021 STI cooperation for the Sustainable and resilient system after COVID-19 from the Russian perspective Karine Haji, researcher, Institute for International Economics and Finance Russian Foreign Trade Academy, Russia Plan of the presentation 1. COVID-19 changes everything 2. STI policies in Russia amid COVID-19 3. How can STI help? The opportunities for future recovery 2 COVID-19 changes everything GLOBAL PHENOMENON The World Health Organisation announced the pandemic just in three months after the first case detected COMMON SET OF Social distancing; MEASURES Lockdown; Travel restrictions; Medical check-ups and speed tests; Mapping and tracking of COVID-19 infected people and their contacts. MORE DIGITAL STI are vital instruments in all speres of human life and society 3 STI policies in Russia amid COVID-19 RAPID E-commerce (including in traditional sectors); DIGITALISATION E-government; remoted work and education. “Sputnik V”, “Sputnik Light”, «EpiVacCorona» and VACCINATION «CoviVac». LEGAL To support STI amid COVID-19. GROUND IT- Two sets of supportive measures. INDUSTRY SUPPORT Olympic movement among children and youth EDUCATIO more places for STI specialists in
    [Show full text]
  • Coronavirus Vaccine Tracker
    https://nyti.ms/2MHNdRL U.S.A. World Health Coronavirus Vaccine Tracker By Carl Zimmer, Jonathan Corum and Sui-Lee Wee Updated April 5, 2021 PHASE 1 PHASE 2 PHASE 3 AUTHORIZED APPROVED ABANDONED 50 35 23 5 8 4 Vaccines Vaccines Vaccines Vaccines Vaccines Vaccines testing safety in expanded in large-scale in early or approved abandoned and dosage safety trials efficacy tests limited use for full use after trials Vaccines typically require years of research and testing before reaching the clinic, but in 2020, scientists embarked on a race to produce safe and effective coronavirus vaccines in record time. Researchers are currently testing 86 vaccines in clinical trials on humans, and 23 have reached the final stages of testing. At least 77 preclinical vaccines are under active investigation in animals. New additions and recent updates April 5 The Walter Reed Army Institute of Research enters Phase 1. April 5 Japanʼs KM Biologics begins Phase 1/2. April 2 Franceʼs OSE Immunotherapeutics enters Phase 1. March 31 The Pfizer-BioNTech vaccine is highly effective in adolescents. March 31 Some Johnson & Johnson doses are delayed by a U.S. factory mix-up. March 30 Chinaʼs Jiangsu Rec-Biotechnology enters Phase 1. March 27 Turkeyʼs Middle East Technical and Bilkent University begin Phase 1. March 25 A vaccine from Chinaʼs Zhongyianke Biotech enters Phase 2. March 23 U.S. officials question the completeness of AstraZenecaʼs trial results. March 23 Daiichi Sankyo and the University of Tokyo enter Phase 1/2. March 22 AstraZenecaʼs vaccine is found to be 79% effective in a large U.S.
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 19 Luglio 2021
    Coronavirus: quello che c’è da sapere – 19 luglio 2021 Sommario Quando è iniziata l’epidemia? ......................................2 Che cosa sono i test sierologici? a cosa servono? ................................26 Quando è arrivata in Italia? ..........................................2 Chi viene colpito dalla malattia Covid-19? ............................................26 A cosa è dovuta l’infezione? .........................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................26 Quanto è diffusa l’epidemia? ....................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....31 Che cosa sono i coronavirus? ...................................................................2 Qual è l’origine del virus? .........................................................................4 Il virus può diventare endemico?............................................................32 Il virus può mutare? ..................................................................................4 Esiste un vaccino? ...................................................................................33 Come si trasmette l’infezione? ...............................................................10 Quali sono le terapie disponibili?............................................................48 I bambini sono più soggetti all’infezione? .............................................14 Quali sono i rischi sanitari legati all’epidemia? .....................................60
    [Show full text]
  • Current Scenario of Sars-Coronavirus 2: Epidemiology; Post-Covid-19 and Global Impacts
    CURRENT SCENARIO OF SARS-CORONAVIRUS 2: EPIDEMIOLOGY; POST-COVID-19 AND GLOBAL IMPACTS Vishnu Priya Sampatha*, Prasannaraj Govindarajb, Ramasamy Subbiah c, Makesh Mohand Address(es): a State-Key Laboratory for Mechanical Behavior of Materials, School of Material Science & Engineering, Xi'an Jiaotong University, Xi'an 710049, China. b Neurochemistry Laboratory, Department of Neurological Sciences, Christian Medical College and Hospital, Vellore 632004, Tamil Nadu, India. c Cardiac Hypertrophy Laboratory, Department of Molecular Biology, School of Biological Sciences, Madurai Kamaraj University, Madurai 625021, Tamil Nadu, India. d Department of Physics, National Institute of Technology, Karnataka (NITK) Surathkal 575025, Karnataka, India. *Corresponding author: [email protected] https://doi.org/10.15414/jmbfs.4066 ARTICLE INFO ABSTRACT Received 11. 12. 2020 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a highly contagious strain of coronavirus that causes Coronavirus Disease 2019 (COVID-19) infection, which has distressed the world's health and wealth. This Global Pandemic outbreak has affected Revised 17. 6. 2021 public health enormously at various customs. The investigation of SARS-CoV-2 is still at infancy; however, based on the available Accepted 29. 6. 2021 reports, this review gives an overview of the epidemiology, genomic landscape, diversity of SARS-CoV-2, viral genome pathogenic Published xx.xx.201x interactions, associating factors for COVID-19 infections, post-COVID-19, disease manifestations with their comorbidities, the major obstacles and the preventive measures along with current vaccine strategies of SARS-CoV-2. This review also summarizes all the Regular article relevant evidence of COVID-19 illness, which can provide valuable information on the SARS-CoV-2 genome and its mode of action strategies, thus delivering additional knowledge about COVID-19.
    [Show full text]
  • Single-Dose Sputnik Light Could Be First Single-Dose Vaccine Launched
    04/06/2021 Single-dose Sputnik Light could be first single-dose vaccine launched in India My Account HOME LATEST TRENDING PREMIUM e-paper Get APP Home >News >India >Single-dose Sputnik Light could be first single-dose vaccine launched in India Single-dose Sputnik Light could be first single-dose vaccine launched in India OPEN APP Sputnik Light has already been approved and trials are already started in some other countries (MINT_PRINT) 1 min read . Updated: 02 Jun 2021, 10:08 AM IST Shalini Bhardwaj, ANI Sputnik Light is a single-dose vaccine that can be useful to boost the country's requirement and target to increase maximum vaccination drive There is a possibility of a speedy launch of single-dose Covid-19 vaccine Sputnik Light in India, and an application seeking regulatory approval for the jab is expected to be filed soon, the sources said on Tuesday. According to the sources Dr. Reddy's in talks with the Government of India to bring Russia's Sputnik Light vaccine to India. MORE FROM THIS SECTION See All https://www.livemint.com/news/india/singledose-sputnik-light-could-be-first-single-dose-vaccine-launched-in-india-11622607843495.html 1/4 04/06/2021 Single-dose Sputnik Light could be first single-dose vaccine launched in India My Account HOME LATEST TRENDING PREMIUM AIIMS entrance exam: This airline will launch Air travel restrictions Gujarat eases Covid-19 Student unions want Supersonic Jet: Sea-npaper Get AcoPPuld be eased, depending restrictions, all offices to The Sputnik Light can become the first single-dose vaccine to be launched in India.
    [Show full text]